Truist Financial Corp Sells 4,418 Shares of Danaher Co. (NYSE:DHR)

Truist Financial Corp decreased its holdings in shares of Danaher Co. (NYSE:DHR) by 0.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 502,219 shares of the conglomerate’s stock after selling 4,418 shares during the period. Truist Financial Corp owned approximately 0.07% of Danaher worth $125,479,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Tsfg LLC lifted its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher in the second quarter worth approximately $25,000. nVerses Capital LLC bought a new position in shares of Danaher in the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher during the first quarter valued at approximately $30,000. Finally, Richardson Financial Services Inc. purchased a new stake in Danaher in the 4th quarter valued at $42,000. 79.05% of the stock is owned by institutional investors.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by company insiders.

Danaher Stock Performance

NYSE DHR opened at $278.02 on Tuesday. The company’s 50 day moving average is $270.77 and its 200-day moving average is $258.06. The firm has a market cap of $205.93 billion, a P/E ratio of 47.12, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period last year, the company earned $2.05 earnings per share. Sell-side analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. TD Cowen lifted their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research report on Friday, September 6th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Stifel Nicolaus upped their target price on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, Evercore ISI cut their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.